PCI Biotech Holding ASA (OSL:PCIB)

Market Cap	64.95M
Revenue (ttm)	6.74M
Net Income (ttm)	-16.42M
Shares Out	37.33M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,014
Average Volume	130,600
Open	1.640
Previous Close	1.740
Day's Range	1.620 - 1.740
52-Week Range	1.100 - 3.500
Beta	1.81
RSI	57.49
Earnings Date	Aug 29, 2025

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 5
• Stock Exchange: Oslo Børs
• Ticker Symbol: PCIB

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.